Exelixis
EXEL
#1677
Rank
$10.22 B
Marketcap
$35.80
Share price
0.82%
Change (1 day)
71.79%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): $0.59 Billion USD

According to Exelixis's latest financial reports the company's current earnings are $2.08 Billion USD. In 2023 the company made an earning of $0.25 Billion USD, an increase over its 2022 earnings that were of $0.23 Billion USD. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) $0.59 B132.95%
2023 $0.25 B9.89%
2022 $0.23 B-20.33%
2021 $0.29 B124.82%
2020 $0.13 B-67.14%
2019 $0.39 B-11.94%
2018 $0.45 B185.09%
2017 $0.15 B-325.82%
2016 -$70.23 Million-58.12%
2015 -$0.17 Billion-37.61%
2014 -$0.27 Billion9.75%
2013 -$0.25 Billion65.96%
2012 -$0.15 Billion-291.63%
2011 $76.99 M-195.59%
2010 -$80.55 Million-42.17%
2009 -$0.14 Billion-18.98%
2008 -$0.18 Billion-6.99%
2007 -$0.19 Billion46.3%
2006 -$0.13 Billion33.25%
2005 -$94.81 Million-30.92%
2004 -$0.14 Billion44.29%
2003 -$95.12 Million12.86%
2002 -$84.29 Million22.79%
2001 -$68.65 Million60.14%
2000 -$42.87 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
$4.17 B 595.25%๐Ÿ‡ฌ๐Ÿ‡ง UK
$7.40 B 1,134.83%๐Ÿ‡ซ๐Ÿ‡ท France
$16.49 B 2,648.76%๐Ÿ‡บ๐Ÿ‡ธ USA
-$6.88 Billion-1,246.85%๐Ÿ‡บ๐Ÿ‡ธ USA
$4.67 B 679.96%๐Ÿ‡บ๐Ÿ‡ธ USA
$18.39 B 2,966.31%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.22 Billion-302.03%๐Ÿ‡บ๐Ÿ‡ธ USA
-$46.61 Million-107.77%๐Ÿ‡บ๐Ÿ‡ธ USA
-$29.04 Million-104.84%๐Ÿ‡บ๐Ÿ‡ธ USA